Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-α

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1671-1677

  Reuben, James M ^a   Lee, Bang Ning ^a   Johnson, Hannah ^a   Fritsche, Herbert ^a   Kantarjian, Hagop M ^a   Talpaz, Moshe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLAST CELL CRISIS; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CYTOKINE PRODUCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL;

ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-2; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE ACTIVATION; REMISSION INDUCTION; T-LYMPHOCYTES; TETRADECANOYLPHORBOL ACETATE; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034108647     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., and Kantarjian, H. M. The biology of chronic myelogenous leukemia. N. Engl. J. Med., 341: 164-172, 1999.
2. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med., 340: 1330-1340, 1999.
3. Sonta, S. I., and Sandberg, A. A. Chromosomes and causation of human cancer and leukemia. XXIV. Unusual and complex Ph1 translocations and their clinical significance. Blood, 50: 691-697, 1977.
4. Rowley, J. D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond.), 243: 290-293, 1973.
5. Golde, D. W., Byers, L. A., Cline, M. J. Chronic myelogenous leukemia cell growth and maturation in liquid culture. Cancer Res., 34: 419-423, 1974.
6. Cortes, J. E., Talpaz, M., and Kantarjian, H. Chronic myelogenous leukemia. A review. Am. J. Med., 100: 555-570, 1996.
7. Kantarjian, H. M., Smith, T. L., McCredie, K. B., Keating, M. J., Walters, R. W., Talpaz, M., Hester, J. P., Bligham, G., Gehan, E., and Freireich, E. J. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood, 86: 1326-1335, 1985.
8. Theologides, A. Unfavorable signs in patients with chronic myelocytic leukemia. Ann. Int. Med., 76: 95-99, 1972.
9. Wiernik, P. H. The current status of therapy for and prevention of blast crisis of chronic myelogenous leukemia. J. Clin. Oncol., 2: 329-335, 1984.
10. Goldman, J. M., and Lu, D-P. New approaches in chronic granulocytic leukemia: origin, prognosis, and treatment. Semin. Hematol., 19: 241-256, 1982.
11. Talpaz, M., McCredie, K. B., Mavligit, G. M., and Gutterman, J. U. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood, 62: 689-692, 1983.
12. Talpaz, M., Katnarjian, H. M., Kurzrock, R., and Gutterman, J. Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin. Hematol., 25: 62-73, 1988.
13. Pane, F., Mostarda, I., Selleri, C., Salzano, R., Raiola, A. M., Luciano, L., Saglio, G., Rotoli, B., and Salvatore, F. BCR/ABL mRNA and the P210(BCR/ABL) protein are downregulated by interferon-α in chronic myelogenous leukemia patients. Blood, 94: 2200-2207, 1999.
14. Kayagaki, N., Yamaguchi, N., Nakayama, M., Eto, H., Okumura, K., and Yagita, H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med., 189: 1451-1460, 1999.
15. Aman, M. J., Rudolf, G., Goldschmitt, J., Aulitzky, W. E., Lam, C., Huber, C., and Peschel, C. Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells. Blood, 82: 2371-2378, 1994.
16. Tilg, H., Mier, J. W., Vogel, W., Aulitzky, W. E., Wiedermann, C. J., Vannier, E., Huber, C., and Dinarello, C. A. Induction of circulating IL-1 receptor antagonist by IFN treatment. J. Immunol., 150: 4687-4692, 1993.
17. Tilg, H., Vogel, W., and Dinarello, C. A. Interferon-a induces circulating tumor necrosis factor receptor p55 in humans. Blood, 85: 433-435, 1995.
18. Peschel, C., Aman, M. J., Rudolf, G., Aulitzky, W. E., and Huber, C. Regulation of the cytokine network by interferon: a potential mechanism of interferon in chronic myelogenous leukemia. Semin. Hematol., 30: 28-31, 1993.
19. Pawelec, G., Rehbein, A., Schlotz, E., and da Silva, P. Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunol. Immunother., 42: 193-199, 1996.
20. Peschel, C., Aulitzky, W. E., and Huber, C. Influence of interferon-α on cytokine expression by the bone marrow microenvironment: impact on treatment of myeloproliferative disorders. Leuk. Lymphoma, 22: 129-134, 1996.
21. Galvani, D. W., and Cawley, J. C. Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Br. J. Haematol., 73: 475-479, 1989.
22. Truitt, R. L., and Atasoylu, A. A. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant., 8: 51-58, 1991.
23. Lucey, D. R., Clerici, M., and Shearer, G. M. Type 1 and type 2 cytokine dysregulation in human infections, neoplastic and inflammatory diseases. Clin. Microbiol. Rev., 9: 532-562, 1996.
24. Lee, B-N., Duvic, M., Tang, C-K., Buenos-Ramos, C., Estrov, Z., and Reuben, J. M. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin. Diagn. Lab. Immunol., 6: 79-84, 1999.
25. Clerici, M., and Shearer, G. M. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today, 15: 575-581, 1994.
26. Jones, G. D., Dlloso, M. M., and Scott, P. Host susceptibility factors to cutaneous leishmaniasis. Frontiers Biosci., 2: D1171-1180, 1998.
27. Lohoff, M., Gessner, A., Bogdan, C., and Rollinghoff, M. The Th1/Th2 paradigm and experimental murine leishmaniasis. Int. Arch. Allergy Immunol., 115: 191-202, 1998.
28. Piro, D. Cytokine networks with infection: mycobacterial infections. Leishmaniasis, human Immunodeficiency virus infection, and sepsis. Pharmacotherapy, 17: 205-223, 1997.
29. Talpaz, M., Kantarjian, H. M., McCredie, K., Trujillo, J. M., Keating, M. J., and Gutterman, J. U. Hematologic remission and cytogenetic improvement induced by recombinant human interferon a A in chronic myelogenous leukemia. N. Engl. J. Med., 314: 1065-1069, 1986.
30. Cortes, J., Fayad, L., Kantarjian, H., O'Brien, S., Lee, M-S., and Talpaz, M. Association of HLA phenotype and response to interferon-α in patients with chronic myelogenous leukemia. Leukemia (Baltimore), 12: 455-462, 1998.
31. Nylander, S., and Kalies, I. Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry. J. Immunol. Methods, 224: 69-76, 1999.
32. Lopez-Cabrera, M., Santis, A. G., Fernandez-Ruiz, E., Blacher, R., Esch, F., Sanchez-Mateos, P., and Sanchez-Madrid, F. Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J. Exp. Med., 178: 537-547, 1993.
33. Sacchi, S., Cortes, J., Kantarjian, H., and Talpaz, M. Effects of interferon-α therapy on lymphocytes subpopulations in patients with chronic myeloid leukemia. Hematopathol. Mol. Hematol., 11: 41-47, 1997.
34. Jung, T., Schauer, U., Heusser, C., Neumann, C., and Rieger, C. Detection of intracellular cytokines by flow cytometry. J. Immunol. Methods, 159: 197-207, 1993.
35. Fiorentino, D. F., Zlotnik, A., Vieira, P., Mosmann, T. R., Howard, M., Moore, K. W., and O'Garra, A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol., 146: 3444-3451, 1991.
36. Taga, K., and Tosato, G. IL-10 inhibits human T cell proliferation and IL-2 production. J. Immunol., 148: 1143-1148, 1992.
37. de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M-G., te Velde, J., Figdor, C., Johnson, K., Kastelein, R., Yssel, H., and de Vries, J. E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med., 174: 915-924, 1991.
38. Taga, K., Mostowski, H., and Tosato, G. Human interleukin-10 can directly inhibit T-cell growth. Blood, 81: 2964-2971, 1993.
39. Yotnda, P., Huseyin, F., Garcia-Pons, F., Garcia, Z., Gourru, G., Vernant, J-P., Lemonnier, F. A., Leblond, V., and Langlade-Demoyen, P. Cytotoxic T cell response against the chirneric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Investig., 101: 2290-2296, 1998.
40. Whittington, R., and Faulds, D. Interleukin-2. A review of its pharmacologic properties and therapeutic use in patients with cancer. Drugs, 46: 446-514, 1993.
41. Weil, D., and Dautry, F. Induction of tumor necrosis factor-α and -β and interferon-γ mRNA by interleukin 2 in murine lymphocytic cell lines. Oncol. Res., 3: 409-414, 1998.
42. Sasiain, M. C., de la Barrera, S., Fink, S., Finiasz, M., Aleman, M., Farina, M. H., Pizzariallo, G., and Valdez, R. Interferon-γ (IFN-γ) and tumour necrosis factor-γ (TNF-γ) are necessary in the early stages of induction of CD4 and CD8 cytotoxic T cells by Mycobacterium leprae heat shock protein (hsp) 65 kD. Clin. Exp. Immunol., 114: 196-203, 1998.
43. Brinkmann, V., Greiger, T., Alkan, S., and Hausser, C. H. Interferon a increases the frequency of Interferon γ-producing human CD4+ T cells. J. Exp. Med., 178: 1655-1663, 1993.
44. Backx, B., Breeders, L., Bot, F. J., and Lowenberg, B. Positive and negative effects of tumor necrosis factor on colony growth from highly purified normal marrow progenitors. Leukemia (Baltimore), 5: 66-70, 1991.
45. Caux, C., Saeland, S., Favre, C., Duvert, V., Mannoni, P., and Banchereau, J. Tumor necrosis factor-γ strongly potentiates interleukin-3, and granulocyte-macrophage colony-stimulating factor-induced proliferation of human CD34+ hematopoietic progenitor cells. Blood, 75: 2292-2298, 1990.
46. Wisniewski, D., Strife, A., Atzpodien, J., and Clarkson, B. D. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia. Cancer Res., 47: 4788-4794, 1987.
47. Kitagawa, M., Saito, I., Kuwata, T., Yoshida, S., Yamaguchi, S., Takahashi, M., Tanizawa, T., Kamiyama, R., and Hirokawa, K. Overexpression of tumor necrosis factor (TNF)-α and Interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia (Baltimore), 11: 2049-2054, 1997.
48. Freedman, M. H., Cohen, A., Grunberger, T., Bunin, N., Luddy, R. E., Saunders, E. F., Shahidi, N., Lau, A., and Estrov, Z. Central role of tumor necrosis factor, GM-CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukemia. Br. J. Haematol., 80: 40-48, 1992.
49. Wetzler, M., Talpaz, M., Lowe, D. G., Baiocchi, G., Gutterman, J. U., and Kurzrock, R. Constitutive expression of leukemia inhibitory factor RNA by human bone marrow stromal cells and modulation by IL-1, TNF-α, and TGF-β. Exp. Hematol., 19: 347-351, 1991.
50. Elbaz, O., Mahmoud, L. A., Touw, I. P., and Lowenberg, B. Analysis of the TNF receptors on human leukemia cells by affinity cross-linking. Br. J. Haematol., 81: 530-532, 1992.
51. Shresta, S., Pham, C. T., Thomas, D. A., Graubert, T. A., and Ley, T. J. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol., 10: 581-587, 1998.
52. Kurzrock, R., Estrov, Z., Kantarjian, H., and Talpaz, M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J. Clin. Oncol., 16: 1526-1531, 1998.